2012 represents a period with robust news flow for emerging immuno-oncology companies
Baker’s Dozen Trying to Beat the Odds in Pancreatic Cancer
October 23, 2011 By 2 Comments
November marks Pancreatic Cancer Awareness Month – a baker’s dozen are trying to beat the odds in treating the disease.
Three Late-Stage Leukemia Company Previews for ASCO
May 8, 2011 By 1 Comment
Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.
To Partner, or Not to Partner: That is the Question
March 10, 2011 By 3 Comments
Traditional wisdom holds that biotechnology companies benefit from collaborations with their larger pharmaceutical peers, which can help validate a company’s technology, provide capital to help fund clinical development, and enable access to experienced clinical, regulatory and commercial infrastructure. While this was certainly true in the early days of biotechnology, the industry has now matured – [...]
Merger Means Billions for Biotechnology?
February 16, 2011 By Leave a Comment
In March 2009, we asked the question “Where Might Genentech Investors Redeploy $47 Billion?” in response to the news that Roche Holding AG (RHHBY.PK) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in cash. We hypothesized that investors seeking biotechnology companies of comparable size and liquidity [...]
Follow MD Becker Partners